AR100420A1 - BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM - Google Patents

BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM

Info

Publication number
AR100420A1
AR100420A1 ARP150101472A ARP150101472A AR100420A1 AR 100420 A1 AR100420 A1 AR 100420A1 AR P150101472 A ARP150101472 A AR P150101472A AR P150101472 A ARP150101472 A AR P150101472A AR 100420 A1 AR100420 A1 AR 100420A1
Authority
AR
Argentina
Prior art keywords
alkoxy
groups
substituted
cycloalkyl
cycloalkyloxy
Prior art date
Application number
ARP150101472A
Other languages
Spanish (es)
Inventor
Hyun Suh Kwee
Du Kim Nam
Sub Lee Moon
Young Song Ji
Jang Wook
Jeoung Kim Won
Sook Kim Ji
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of AR100420A1 publication Critical patent/AR100420A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud se refiere a un derivado bicíclico que tiene actividad inhibidora contra los transportadores relacionados con ia glucosa de sodio (SGLTs) presentes en los intestinos y en los riñones, o una de sus sales, isómeros, hidratos o solvatos aceptables desde el punto de vista farmacéutico, y una composición farmacéutica que los incluye como principio activo, que inhiben en forma efectiva la actividad de SGLT, y así puede usarse como un agente terapéutico para tratar enfermedades causadas por hiperglucemia, tales como diabetes que incluye diabetes dependiente de la insulina (diabetes mellitus tipo I) y diabetes no dependiente de la insulina (diabetes mellitus tipo II), complicaciones diabéticas, y obesidad. Reivindicación 1: Un derivado bicíclico representado por fórmula (1), o una de sus sales, isómeros, hidratos o solvatos aceptables desde el punto de vista farmacéutico, en donde A es -O- o -CH₂-; el anillo B se selecciona del grupo que consiste en las fórmulas estructurales (2), (3) y (4); R¹, R², y R³ son cada uno de manera independiente H, halógeno, hidroxi, alquilo C₁₋₈, alquenilo C₂₋₇, alquinilo C₂₋₇, cicloalquilo C₃₋₆, alcoxi C₁₋₈, o cicloalquiloxi C₃₋₆, en donde el alquilo C₁₋₈, alquenilo C₂₋₇, alquinilo C₂₋₇, cicloalquilo C₃₋₆, alcoxi C₁₋₈, y cicloalquiloxi C₃₋₆ pueden estar sustituidos cada uno de manera independiente con 1 hasta 5 grupos fluoro, alquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₈, heterocicloalquiloxi de 3 a 6 miembros, o grupos alquilsulfonilo C₁₋₃, en donde el alcoxi C₁₋₈ puede sustituirse con uno a dos alcoxi C₁₋₈ o grupos cicloalquiloxi C₃₋₆; R¹ y R² sustituidos en dos átomos de carbono adyacentes pueden unirse para formar un puente alquileno C₃₋₅, donde uno a dos grupos metileno en el puente alquileno C₃₋₅ puede reemplazarse cada uno de manera independiente con -O-, -S-, -S(=O)-, -S(=O)₂-, -C(=O)-, o -N(-R⁴)-, y los grupos metileno no reemplazados pueden estar sustituidos cada uno de manera independiente con 1 hasta 4 halógenos o grupos metilo; R⁴ es H o bencilo; y el heterocicloalquilo incluye por lo menos un heteroátomo seleccionado del grupo que consiste en O, N, y S.The present application refers to a bicyclic derivative that has inhibitory activity against transporters related to sodium glucose (SGLTs) present in the intestines and kidneys, or one of its salts, isomers, hydrates or solvates acceptable from the point of pharmaceutical view, and a pharmaceutical composition that includes them as active ingredient, that effectively inhibit the activity of SGLT, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes that includes insulin-dependent diabetes ( Type I diabetes mellitus) and non-insulin dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity. Claim 1: A bicyclic derivative represented by formula (1), or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, wherein A is -O- or -CH₂-; Ring B is selected from the group consisting of structural formulas (2), (3) and (4); R¹, R², and R³ are each independently H, halogen, hydroxy, C₁₋₈ alkyl, C₂₋₇ alkenyl, C₂₋₇ alkynyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, or C₃₋₆ cycloalkyloxy, in where C₁₋₈ alkyl, C₂₋₇ alkenyl, C₂₋₇ alkynyl, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, and C₃₋₆ cycloalkyloxy can each be independently substituted with 1 to 5 fluoro groups, C₁₋ alkyl ₄, C₃₋₆ cycloalkyl, C₁₋₈ alkoxy, 3 to 6 membered heterocycloalkyloxy, or C alqu alkylsulfonyl groups, wherein the C₁₋₈ alkoxy can be substituted with one to two C₁₋₈ alkoxy or C₃₋₆ cycloalkyloxy groups; R¹ and R² substituted on two adjacent carbon atoms can be joined to form a C₃₋₅ alkylene bridge, where one to two methylene groups on the C₃₋₅ alkylene bridge can each be independently replaced with -O-, -S-, -S (= O) -, -S (= O) ₂-, -C (= O) -, or -N (-R⁴) -, and the unsubstituted methylene groups can each be independently substituted with 1 up to 4 halogens or methyl groups; R⁴ is H or benzyl; and the heterocycloalkyl includes at least one heteroatom selected from the group consisting of O, N, and S.

ARP150101472A 2014-05-13 2015-05-13 BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AR100420A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140057428A KR20150130177A (en) 2014-05-13 2014-05-13 2,3-dihydrobenzofuran derivatives as an sglt inhibitor and pharmaceutical composition comprising same

Publications (1)

Publication Number Publication Date
AR100420A1 true AR100420A1 (en) 2016-10-05

Family

ID=54844675

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101472A AR100420A1 (en) 2014-05-13 2015-05-13 BICYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM

Country Status (2)

Country Link
KR (1) KR20150130177A (en)
AR (1) AR100420A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6667008B2 (en) * 2016-01-04 2020-03-18 ジェイイー アイエル ファーマシューティカル カンパニー リミテッド C-Glucoside derivative containing a fused phenyl ring or a pharmaceutically acceptable salt thereof, a method for producing the same, and a pharmaceutical composition containing the same
KR20240047952A (en) * 2022-10-05 2024-04-12 주식회사 대웅제약 Pharmaceutical composition for preventing or treating nephropathy and/or diabetes containing enavogliflozin

Also Published As

Publication number Publication date
KR20150130177A (en) 2015-11-23

Similar Documents

Publication Publication Date Title
AR114164A1 (en) PYRIDOPYRIMIDINONES SUBSTITUTED WITH BENZYLAMINE AND DERIVATIVES AS INHIBITORS OF SOS1
EA201990518A1 (en) PYRAZOLOPYRIDINE DERIVATIVES HAVING THE GLP-1 RECEPTOR EFFECT
ECSP20070854A (en) HETEROARYL TETRACYCLIC COMPOUNDS
CR20150628A (en) DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES
CU20160087A7 (en) INDAZOLCARBOXAMIDS, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM
BR112017007662A8 (en) Compound, pharmaceutical composition and use of a compound
CO6650337A2 (en) Novel 3-hydroxy-5-arylisothiazole derivatives
UY36308A (en) INHIBITORS OF HISTONE ACETILTRANSPHERASES SPIROCYCLES (HAT) AND METHODS FOR USE
PE20181778A1 (en) INDOLINE DERIVATIVES SUBSTITUTE AS INHIBITORS OF DENGUE VIRAL REPLICATION
CR20160523A (en) IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER
CR20150472A (en) USE OF PIRAZOLOPIRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd-RELATED DISORDERS
PE20180796A1 (en) PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII
UY37098A (en) ROR-GAMMA MODULATORS
CU20150014A7 (en) 1,4-DISPOSED PIRIDAZINE ANALOGS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO THE DEFICIENCY OF SMN
AR095034A1 (en) THE USE OF THE RECEPTOR 2 AGONISTS OF THE PEPTIDE FORMULA FOR THE TREATMENT OF EYE INFLAMMATORY DISEASES
BR112016018548A2 (en) compound, acid, medicine, and use of a compound.
UY36465A (en) CARBAMOILPIRIDONE POLICYCLY COMPOUNDS AND THEIR PHARMACEUTICAL USE
UY35263A (en) THERAPEUTIC COMPOUNDS
CR20150378A (en) TETRACYCLIC COMPOUNDS REPLACED WITH HETEROCICLE AND METHODS OF USE OF THE SAME FOR THE TREATMENT OF VIVIC DISEASES
AR099569A1 (en) INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
CL2016000026A1 (en) New azabenzimidazole derivatives
UY36123A (en) CARBOXAMIDE DERIVATIVES
CO2018001700A2 (en) Derivatives of n- [1h-benzimidazol-2-yl] methyl-pyrazin-2-yl-carboxamide, compositions and methods of preparation thereof
PE20211595A1 (en) 2,6-DIAMINOPYRIDINE COMPOUNDS
AR096338A1 (en) (CIANO-DIMETHYL-METHYL) -ISOXAZOLS AND - [1,3,4] TIADIAZOLES

Legal Events

Date Code Title Description
FB Suspension of granting procedure